Last 2,032 GBp
Change Today -11.00 / -0.54%
Volume 311.4K
HIK On Other Exchanges
As of 11:35 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

hikma pharmaceuticals plc (HIK) Snapshot

2,053 GBp
Previous Close
2,043 GBp
Day High
2,053 GBp
Day Low
2,002 GBp
52 Week High
12/9/14 - 2,065 GBp
52 Week Low
01/27/14 - 1,171 GBp
Market Cap
Average Volume 10 Days
1.56 GBp
Shares Outstanding
0.21 GBp
Dividend Yield

Related News

No related news articles were found.

hikma pharmaceuticals plc (HIK) Related Businessweek News

View More BusinessWeek News

hikma pharmaceuticals plc (HIK) Details

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms in the Middle East and North Africa, the United States, and Europe. It operates through three segments: Branded, Injectable, and Generic. The Branded segment offers 499 products in 1,256 dosage strengths and forms, which lie in the anti-infective, cardiovascular, central nervous system (CNS), and diabetes therapeutic areas. The Injectables segment markets 200 branded and non-branded products in 379 dosage strengths and forms with a focus on CNS, anti-infective, musculoskeletal, cardiovascular, and oncological therapeutic areas. This segment also offers sterile liquid, powder, lyophilized, and cytotoxic products. The Generics segment provides 11 products in 44 dosage strengths and forms for various therapeutic areas including analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS, respiratory, hormonal, and others. This segment markets its products to chain stores, wholesalers, distributors, health systems, and governmental agencies in the form of tablets, capsules, solutions, and suspensions. In addition, the company offers anesthetics, anti-histamines, gastroenterology and metabolism, dermatology, genitourinary system, transplantation, vitamins and supplements, and miscellaneous products. Further, it manufactures plastic specialized medicinal sterile containers and API; and conducts bio-equivalency studies. The company was founded in 1978 and is based in London, the United Kingdom.

7,067 Employees
Last Reported Date: 03/11/14
Founded in 1978

hikma pharmaceuticals plc (HIK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $2.4M
Executive Vice Chairman, Chief Executive Offi...
Total Annual Compensation: $1.6M
Compensation as of Fiscal Year 2013.

hikma pharmaceuticals plc (HIK) Key Developments

Hikma Pharmaceuticals plc Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 10:00 AM

Hikma Pharmaceuticals plc Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 10:00 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.

Hikma Pharmaceuticals plc Appoints Pamela Kirby as Independent Non-Executive Director, with Effect from 1 December 2014

Hikma Pharmaceuticals plc announced the appointment of Pamela Kirby as an independent non-executive director of the company with effect from 1 December 2014. Kirby will join the Audit, Remuneration and Compliance, Responsibility and Ethics (CRE) Committees. Pamela Kirby was CEO of Quintiles Transnational Corp. and has held senior executive positions in F Hoffmann-La Roche Ltd. and AstraZeneca plc.

Hikma Pharmaceuticals plc Provides Revenue Guidance for the Full Year 2014

Hikma Pharmaceuticals plc provided revenue guidance for the full year 2014. For the period, the company expects group revenue growth of around 7%.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HIK:LN 2,032.00 GBp -11.00

HIK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $38.06 USD -0.35
BTG PLC 804.00 GBp -1.50
Richter Gedeon Nyrt 3,401 +31.00
Impax Laboratories Inc $31.32 USD +0.54
STADA Arzneimittel AG €25.80 EUR -0.222
View Industry Companies

Industry Analysis


Industry Average

Valuation HIK Industry Range
Price/Earnings 20.5x
Price/Sales 4.3x
Price/Book 5.5x
Price/Cash Flow 20.5x
TEV/Sales 4.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HIKMA PHARMACEUTICALS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at